• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

  

FDA Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 5.45MB)

 

Addendum(1) to the FDA Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 3.15MB)

 

Addendum(2) to the FDA Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 831KB)

 

Errata to the FDA Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 11.3KB)

 

 

Novartis Pharmaceuticals Corporation

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

Novartis Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 2.07MB)

 

 Errata to the Novartis Briefing Information, Fingolimod Capsules, for the June 10, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PDF – 15.9KB)